KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Teva Pharmaceutical Industries (TEVA) Operating Margin (2016 - 2025)

Teva Pharmaceutical Industries (TEVA) has disclosed Operating Margin for 10 consecutive years, with 6.37% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Operating Margin rose 705.0% year-over-year to 6.37%, compared with a TTM value of 26.67% through Dec 2025, up 2850.0%, and an annual FY2025 reading of 12.5%, up 1433.0% over the prior year.
  • Operating Margin was 6.37% for Q4 2025 at Teva Pharmaceutical Industries, down from 44.35% in the prior quarter.
  • Across five years, Operating Margin topped out at 44.35% in Q3 2025 and bottomed at 25.54% in Q2 2022.
  • Average Operating Margin over 5 years is 4.72%, with a median of 4.14% recorded in 2021.
  • The sharpest move saw Operating Margin skyrocketed 12518bps in 2021, then crashed -4043bps in 2022.
  • Year by year, Operating Margin stood at 1.9% in 2021, then plummeted by -1367bps to 24.1% in 2022, then surged by 170bps to 16.96% in 2023, then crashed by -104bps to 0.69% in 2024, then surged by 1029bps to 6.37% in 2025.
  • Business Quant data shows Operating Margin for TEVA at 6.37% in Q4 2025, 44.35% in Q3 2025, and 43.01% in Q2 2025.